Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Article Details
- CitationCopy to clipboard
Ghazi A, Trikha A, Calhoun WJ
Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.
- PubMed ID
- 22136436 [ View in PubMed]
- Abstract
INTRODUCTION: Benralizumab is a monoclonal antibody that binds the alpha subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. AREAS COVERED: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. EXPERT OPINION: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Benralizumab Interleukin-5 receptor subunit alpha Protein Humans YesAntibodyDetails Benralizumab Low affinity immunoglobulin gamma Fc region receptor III-A Protein Humans YesBindingDetails